Viral SafetyGive your patients confidence in their therapy
GAMMAGARD LIQUID therapy is treated with a dedicated 3-step process specifically designed for viral inactivation/removal.1
Solvent/Detergent Treatment
Inactivates lipid-enveloped viruses to below detection limits
35nm Nanofiltration
Lipid and non-lipid-enveloped viruses are further removed
Low pH Incubation
Final inactivation of viruses is accomplished with low pH and elevated temperature
GAMMAGARD LIQUID therapy is sourced and processed exclusively from plasma collected at FDA-registered donor sites.1
- Donations are individually screened for HBsAg and for antibodies to HIV-1, HIV-2, and HCV*
- Mini-pools of collected plasma are further tested with FDA-approved nucleic acid testing
- IgGs are purified from plasma pools with a modified Cohn-Oncley fractionation process, and cation and anion exchange chromatography
As with all plasma-derived therapeutics, the potential to transmit infections agents cannot be totally eliminated.
Learn about the steps Baxter is taking to protect GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% against specific viral agents.
*EMCV (encephalomyocarditis virus), HAV (hepatitis A virus), MMV (mice minute virus), B19V (human parvovirus B19), HBsAg (hepatitis B surface antigen), HIV (human immunodeficiency virus), HCV (hepatitis C virus)
Please see the detailed Important Risk Information and Full Prescribing Information for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] for full prescribing details.
- GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% package insert. Westlake Village, CA. Baxter International Inc.; October 2009.
